Viking Therapeutics VKTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $150.15M+263% | $153.46M+395% | $89.95M+295% | $60.15M+153% | $41.39M+71.7% | ||
| $13.98M-0.7% | $11.28M-26.0% | $8.61M-37.5% | $14.42M+40.2% | $14.08M+41.2% | ||
| $164.13M+196% | $164.74M+256% | $98.56M+170% | $74.57M+119% | $55.47M+62.8% | ||
| -$164.13M-196% | -$164.74M-256% | -$98.56M-170% | -$74.57M-119% | -$55.47M-62.8% | ||
| $5.8M-41.2% | $7.04M-35.1% | $7.77M-32.6% | $9.03M-23.6% | $9.86M+46.2% | ||
| $5.8M-41.1% | $7.08M-34.6% | $7.77M-33.1% | $9.01M-23.6% | $9.84M+46.5% | ||
| -$158.33M-247% | -$157.66M-345% | -$90.79M-264% | -$65.56M-195% | -$45.63M-66.8% | ||
| -$1.37-234% | -$1.39-334% | -$0.81-268% | -$0.58-190% | -$0.41-57.7% | ||
| -$164.13M-196% | -$164.74M-256% | -$98.56M-170% | -$74.57M-119% | -$55.47M-62.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Viking Therapeutics profitable?
- Viking Therapeutics is not currently profitable: it reported a net loss of $472.3M over the trailing twelve months.
- What is Viking Therapeutics's earnings per share?
- Viking Therapeutics's diluted EPS over the trailing twelve months is $-4.15.
- Where does Viking Therapeutics's income statement data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.